Drug Search Results
More Filters [+]

Enoxacin

Alternative Names: enoxacin, penetrex
Latest Update: 2024-08-05
Latest Update Note: News Article

Product Description

McGill University is developing Enoxacin as a treatment for Amyotrophic Lateral Sclerosis (ALS). (Sourced from: https://www.clinicaltrials.gov/study/NCT04840823)

Mechanisms of Action: TOP2 Inhibitor,ATPase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Egypt | Germany | India | Ireland | Morocco | New Zealand | Pakistan | Peru | Portugal | Taiwan | Turkey | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: McGill University
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Enoxacin

Countries in Clinic: Canada

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Amyotrophic Lateral Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

REALS-1

P2

Completed

Amyotrophic Lateral Sclerosis

2023-11-15

Recent News Events